Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

British Journal of Haematology

Volumn 157, Issue 5, 2012, Pages 553-563

  Nishihori, Taiga ^a,b   Alekshun, Todd J ^b   Shain, Kenneth ^a,b   Sullivan, Daniel M ^a,b   Baz, Rachid ^a   Perez, Lia ^a,b   Pidala, Joseph ^a,b   Kharfan Dabaja, Mohamed A ^a,b   Ochoa Bayona, Jose L ^a,b   Fernandez, Hugo F ^a,b   Yarde, Danielle N ^a   Oliveira, Vasco ^a   Fulp, William ^a   Han, Gang ^a   Kim, Jongphil ^a,b   Chen, Dung Tsa ^a,b   Raychaudhuri, Jyoti ^a,b   Dalton, William ^b   Anasetti, Claudio ^a,b   Alsina, Melissa ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Autologous transplantation; Bortezomib; DNA repair pathway; Fanconi anaemia; Multiple myeloma

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; BRCA2 PROTEIN; DEXAMETHASONE; DOXORUBICIN; FANCONI ANEMIA GROUP F PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; MESSENGER RNA; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CORRELATIONAL STUDY; CRANIAL NEUROPATHY; CYTOKINE RELEASE SYNDROME; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; KARYOTYPE; LUNG DISEASE; LUNG HEMORRHAGE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY RESISTANT MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SENSORY NEUROPATHY; STEM CELL; STEM CELL MOBILIZATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE PROGRESSION; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SALVAGE THERAPY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84862804479     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09099.x     Document Type: Article

References (45)

1. Alexanian, R. & Dimopoulos, M. (1994) The treatment of multiple myeloma. New England Journal of Medicine, 330, 484-489.
2. Alexanian, R., Weber, D., Delasalle, K., Handy, B., Champlin, R. & Giralt, S. (2004) Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplantation, 34, 229-234.
3. Andela, V.B., Schwarz, E.M., Puzas, J.E., O'Keefe, R.J. & Rosier, R.N. (2000) Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Research, 60, 6557-6562.
4. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91-97.
5. Berenson, J., Yang, H., Sadler, K., Jarutirasarn, S., Vescio, R., Mapes, R., Purner, M., Lee, S., Wilson, J., Morrison, B., Adams, J., Schenkein, D. & Swift, R. (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 24, 937-944.
6. Bross, P.F., Kane, R., Farrell, A.T., Abraham, S., Benson, K., Brower, M.E., Bradley, S., Gobburu, J.V., Goheer, A., Lee, S.L., Leighton, J., Liang, C.Y., Lostritto, R.T., McGuinn, W.D., Morse, D.E., Rahman, A., Rosario, L.A., Verbois, S.L., Williams, G., Wang, Y.C. & Pazdur, R. (2004) Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clinical Cancer Research, 10, 3954-3964.
7. Chen, Q., Van der Sluis, P., Boulware, D., Hazlehurst, L. & Dalton, W. (2005) The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood, 106, 698-705.
8. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875-1883.
9. Dalton, W.S., Hazlehurst, L., Shain, K., Landowski, T. & Alsina, M. (2004) Targeting the bone marrow microenvironment in hematologic malignancies. Seminars in Hematology, 41, 1-5.
10. Damiano, J.S., Cress, A.E., Hazlehurst, L.A., Shtil, A.A. & Dalton, W.S. (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93, 1658-1667.
11. Damiano, J.S., Hazlehurst, L.A. & Dalton, W.S. (2001) Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia, 15, 1232-1239.
12. Drake, M., Iacobelli, S., van Biezen, A., Morris, C., Apperley, J., Niederwieser, D., Björkstrand, B., Gahrton, G. & European Group for Blood and Marrow Transplantation and the European Leukemia Net. (2010) Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica, 95, 804-809.
13. Durie, B., Harousseau, J., Miguel, J., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
14. Gertz, M.A., Kumar, S., Lacy, M.Q., Dispenzieri, A., Dingli, D., Hayman, S.R., Buadi, F.K. & Hogan, W.J. (2010) Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood, 115, 2348-2353; quiz 2560.
15. Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412-3420.
16. Harousseau, J.L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., Michallet, M., Maisonneuve, H., Benboubker, L., Maloisel, F., Petillon, M.O., Webb, I., Mathiot, C. & Moreau, P. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. Journal of Clinical Oncology, 28, 4621-4629.
17. Hazlehurst, L., Enkemann, S., Beam, C., Argilagos, R., Painter, J., Shain, K., Saporta, S., Boulware, D., Moscinski, L., Alsina, M. & Dalton, W. (2003) Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Research, 63, 7900-7906.
18. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071-3076.
19. Howlett, N.G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., De Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G., Ikeda, H., Fox, E.A. & D'Andrea, A.D. (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science, 297, 606-609.
20. Huang, Y., Johnson, K.R., Norris, J.S. & Fan, W. (2000) Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Research, 60, 4426-4432.
21. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. & Forman, D. (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69-90.
22. Kim, J.Y., Lee, S., Hwangbo, B., Lee, C.T., Kim, Y.W., Han, S.K., Shim, Y.S. & Yoo, C.G. (2000) NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis. Biochemical and Biophysical Research Communications, 273, 140-146.
23. Koreth, J., Cutler, C., Djulbegovic, B., Behl, R., Schlossman, R., Munshi, N., Richardson, P., Anderson, K., Soiffer, R. & Alyea, E.P., 3rd (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biology of Blood and Marrow Transplantation, 13, 183-196.
24. Kumar, S., Lacy, M.Q., Dispenzieri, A., Rajkumar, S.V., Fonseca, R., Geyer, S., Allmer, C., Witzig, T.E., Lust, J.A., Greipp, P.R., Kyle, R.A., Litzow, M.R. & Gertz, M.A. (2004) High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplantation, 34, 161-167.
25. Kumar, S., Rajkumar, S., Dispenzieri, A., Lacy, M., Hayman, S., Buadi, F., Zeldenrust, S., Dingli, D., Russell, S., Lust, J., Greipp, P., Kyle, R. & Gertz, M. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
26. Kumar, A., Kharfan-Dabaja, M., Glasmacher, A. & Djulbegovic, B. (2009) Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. Journal of the National Cancer Institute, 101, 100-106.
27. Lonial, S., Kaufman, J., Tighiouart, M., Nooka, A., Langston, A.A., Heffner, L.T., Torre, C., McMillan, S., Renfroe, H., Harvey, R.D., Lechowicz, M.J., Khoury, H.J., Flowers, C.R. & Waller, E.K. (2010) A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clinical Cancer Research, 16, 5079-5086.
28. Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, J.M., Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. & Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 1136-1144.
29. Meads, M.B., Gatenby, R.A. & Dalton, W.S. (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nature Reviews Cancer, 9, 665-674.
30. Mitsiades, N., Mitsiades, C., Richardson, P., Poulaki, V., Tai, Y., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T., Schlossman, R., Munshi, N., Hideshima, T. & Anderson, K. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377-2380.
31. Mudry, R.E., Fortney, J.E., York, T., Hall, B.M. & Gibson, L.F. (2000) Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood, 96, 1926-1932.
32. Nakanishi, K., Yang, Y.G., Pierce, A.J., Taniguchi, T., Digweed, M., D'Andrea, A.D., Wang, Z.Q. & Jasin, M. (2005) Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proceedings of the National Academy of Sciences of the United States of America, 102, 1110-1115.
33. Palombella, V.J., Rando, O.J., Goldberg, A.L. & Maniatis, T. (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell, 78, 773-785.
34. Rajkumar, S., Jacobus, S., Callander, N., Fonseca, R., Vesole, D., Williams, M., Abonour, R., Siegel, D., Katz, M., Greipp, P. & E. C. O. Group (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology, 11, 29-37.
35. Richardson, P., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R., Kuter, D., Limentani, S., Lee, S., Hideshima, T., Esseltine, D., Kauffman, M., Adams, J., Schenkein, D. & Anderson, K. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
36. Richardson, P., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J., Bladé, J., Boccadoro, M., Cavenagh, J., Dalton, W., Boral, A., Esseltine, D., Porter, J., Schenkein, D. & Anderson, K. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
37. Richardson, P., Weller, E., Lonial, S., Jakubowiak, A., Jagannath, S., Raje, N., Avigan, D., Xie, W., Ghobrial, I., Schlossman, R., Mazumder, A., Munshi, N., Vesole, D., Joyce, R., Kaufman, J., Doss, D., Warren, D., Lunde, L., Kaster, S., Delaney, C., Hideshima, T., Mitsiades, C., Knight, R., Esseltine, D. & Anderson, K. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 116, 679-686.
38. Roussel, M., Moreau, P., Huynh, A., Mary, J., Danho, C., Caillot, D., Hulin, C., Fruchart, C., Marit, G., Pégourié, B., Lenain, P., Araujo, C., Kolb, B., Randriamalala, E., Royer, B., Stoppa, A., Dib, M., Dorvaux, V., Garderet, L., Mathiot, C., Avet-Loiseau Harousseau, H., Attal, J. & M. I. F. d. M. (IFM). (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood, 115, 32-37.
39. San Miguel, J., Schlag, R., Khuageva, N., Dimopoulos, M., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M., Palumbo, A., Samoilova, O., Dmoszynska, A., Abdulkadyrov, K., Schots, R., Jiang, B., Mateos, M., Anderson, K., Esseltine, D., Liu, K., Cakana, A., van de Velde, H. & Richardson, P. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
40. Sher, T., Miller, K., Deeb, G., Lee, K. & Chanan-Khan, A. (2010) Plasma cell leukaemia and other aggressive plasma cell malignancies. British Journal of Haematology, 150, 418-427.
41. Singhal, S., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S. & Mehta, J. (2002) Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplantation, 30, 673-679.
42. Sung, P. & Klein, H. (2006) Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nature Reviews Molecular Cell Biology, 7, 739-750.
43. Vesole, D., Barlogie, B., Jagannath, S., Cheson, B., Tricot, G., Alexanian, R. & Crowley, J. (1994) High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood, 84, 950-956.
44. Woodruff, R.K., Wadsworth, J., Malpas, J.S. & Tobias, J.S. (1979) Clinical staging in multiple myeloma. British Journal of Haematology, 42, 199-205.
45. Yarde, D.N., Oliveira, V., Mathews, L., Wang, X., Villagra, A., Boulware, D., Shain, K.H., Hazlehurst, L.A., Alsina, M., Chen, D.T., Beg, A.A. & Dalton, W.S. (2009) Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Research, 69, 9367-9375.